Along these lines, prostate-specific membrane antigen (PSMA) inhibitors labeled with a variety of radionuclides have gained momentum in PCa diagnosis and therapy due to the high-density expression of PSMA in PCa [5,6]. Here, FOLH1 is linked to posterior cortical atrophy.